S&P Futures
5,888.00 -4.50 (-0.08%) Dow Futures
43,045.00 -124.00 (-0.29%) Nasdaq Futures
20,519.00 -23.00 (-0.11%) Russell 2000 Futures
2,244.80 -1.40 (-0.06%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,753.10 -6.70 (-0.24%)
Brii Biosciences Limited (2137.HK)
| Previous Close | 1.070 |
| Open | 1.060 |
| Bid | 1.050 x N/A |
| Ask | 1.060 x N/A |
| Day's Range | 1.040 - 1.060 |
| 52 Week Range | 0.850 - 3.500 |
| Volume | |
| Avg. Volume | 1,449,567 |
| Market Cap | 774.844M |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.390 |
| Earnings Date | Aug 19, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.99 |
PR NewswireBrii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, presented new data from two Phase 2 studies evaluating BRII-179 either as a combination therapy with BRII-835 (elebsiran) or as an add-on therapy to pegylated interferon-alpha (PEG-IFNα) treatment for chronic hepatitis B virus (HBV) infection at the EASL™ (European Association for the Study of
- PR Newswire
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designations for BRII-877 (tobevibart), an investigational broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) and BRII-835 (elebsiran), a
